A Randomised Controlled Trial for People With Established Type 2 Diabetes During Ramadan: Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen: The 'Can Do Ramadan' Study
Phase of Trial: Phase IV
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Canagliflozin (Primary) ; Gliclazide; Glimepiride; Pioglitazone; Repaglinide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms Can Do Ramadan
- Sponsors Janssen Pharmaceuticals
- 01 Oct 2017 Status changed from recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 21 Jul 2016 Status changed from not yet recruiting to recruiting.